N/A N=21 Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Prostate Embolization for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
Phase 3 N=420 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy
Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371
N/A N=9 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Prostatic Hyperplasia, Benign · Enlarged Prostate With Lower Urinary Tract Symptoms
Primary: Number of Participants With Adverse Events — 3 Participants
Phase 2 N=92 Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…
N/A N=28 Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
N/A N=45 Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH)
Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…
Phase 2 N=17 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis · Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Global Response Assessment — 2 participants
Phase 4 N=1,658 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
Prostatic Hyperplasia
Primary: Number of Men With Confirmed Diagnosis of BPH — 386; 437 Participants
N/A N=140 Prostate Cancer - Patient Empowerment Program
Prostate Cancer
Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 3 N=528 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hypertrophy
Primary: IPSS Change From Baseline — -5.6 Units on a scale — p=<0.001
Phase 3 N=478 Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Prostate Cancer
Primary: Time to Progression — 683.0; 549.0 days — p=0.76
N/A N=60 The Prostate Immobilization Device Study
Adenocarcinoma of the Prostate
Primary: Deviation of the Prostate Rectal Interface From Its Position at Time of Simulation. — .319; .095 CENTIMETERS
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
N/A N=44 Effect of Weight Loss on Prostate Cancer Pathology
Obesity · Prostate Cancer
Primary: Apoptotic Index of the Highest Gleason Grade Malignant Epithelium in the Radical Prostatectomy Specimen Obtained After 8-weeks of the Dietary Intervention — 6.9; 5.0…
N/A N=40 Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Urinary Incontinence
Primary: Time to Continence — 95 Days to Continence
Phase 2 N=31 Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]
Healthy
Primary: Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel. — 2.8; 3.1; 0.6; 0.4 ng/g
N/A N=440 Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Proportion of Responders at the End of 8-week — 60.6; 36.8 percentage of participants
Phase 2 N=33 Green Tea Extract and Prostate Cancer
Prostate Cancer
Primary: Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer — 0.86 ng/mL — p==0.027
N/A N=743 Treatment Preference and Patient Centered Prostate Cancer Care
Prostate Cancer
Primary: Change in Satisfaction With Care — 0.26; 0.07; 0.28; 0.06 units on a scale
N/A N=95 Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
Prostate Cancer
Primary: Micro-Ultrasound Detection of High Grade Prostate Cancer (Gleason Score ≥7) vs. Surgical Pathology — 38; 50 participants
Phase 2 N=39 Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Prostate Cancer
Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc
N/A N=284 GET FIT Prostate: A Randomized Controlled Exercise Trial
Prostate Carcinoma
Primary: Number of Falls — 0.29; .33; .38 Average fall count per 6 months
N/A N=101 Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Benign Prostatic Hyperplasia (BPH)
Primary: Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment — 45.5 percentage
N/A N=400 Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Prostatic Hyperplasia
Primary: Number of Participants Reporting Compliance With Medication — 239; 161 participants
N/A N=35 High-Dose Stereotactic Radiation for Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants
Phase 2 N=97 Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Prostatic Hyperplasia
Primary: Rate of Progression to Prostate Cancer (PCa) — 4; 6 participants
Phase 2 N=64 Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
Prostate Cancer
Primary: Time to Treatment Failure — 4.5; 6.9 Months
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g